ApprovalTrail

Approval · Notice of Compliance 34938 · 2025

OLIMEL 3.3% E: Notice of Compliance 34938

Issued March 4, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
34938
Date
March 4, 2025
Company
Baxter CorporationMississauga, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Change in the specification for the drug product

Products in this notice

BrandDINStatus today
OLIMEL 3.3% ENot yet assigned—
OLIMEL 4.4% ENot yet assigned—
OLIMEL 5.7% ENot yet assigned—
OLIMEL 7.6% ENot yet assigned—
PERIOLIMEL 2.5% ENot yet assigned—

Medicinal ingredients